Updated
- Log In
- Newsletters
-
Subscribe
Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Marijuana
Cowen Says Tilray Is Still a Buy Despite Spate of Underwhelming Pot Earnings
Cowen lowers Tilray's price target but maintains its 'outperform' rating.
Canopy Growth Slides After Quarterly Revenue Misses Estimates
Canopy Growth's fiscal second-quarter revenue misses analysts' estimates.
Tilray Slips as Revenue Misses and EPS Is a Little Better Than Estimates
Tilray shares are falling after reporting mixed third-quarter results.
Cronos Swings to Loss Despite Revenue Spike, Stock Falls
Cronos sells 213% more cannabis by kilograms in the third quarter than it did a year ago.
How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray
With Tilray set to report earnings after today's closing bell, we're rewinding to our sit-down with CEO Brendan Kennedy.
Aurora Cannabis Tanks Despite Strong Earnings Growth
Aurora Cannabis reports fiscal first-quarter revenue growth of 260%.
Jim Cramer's Take on the Cannabis Craze
Another cannabis craze?
IGC, Tilray and Other Pot Stocks Gain After Sessions Quits as Attorney General
IGC and Tilray rise by double-digit percentages and other weed stocks rally as anti-pot attorney general steps down and voters back cannabis sales in three states.
Pot Stocks Pop After Michigan Legalizes Recreational Cannabis Use
Michigan becomes the 10th U.S. state to legalize the recreational use of marijuana.
CV Sciences CEO on the Future of CBD in Healthcare
CV Sciences CEO discusses the medical applications of CBD at Jim Cramer's teach in.